Prospects of postoperative prostate cancer adaptive radiation therapy

Phase 2

Recruiting

• Conditions: C61; Malignant neoplasm of prostate

• Registration Number: DRKS00033235
• Lead Sponsor: Klinik und Poliklinik für Strahlentherapie des Universitätsklinikums Essen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

Patients with histologically confirmed, localized or locally advanced prostate cancer who are to receive postoperative radiotherapy of the prostate after an interdisciplinary tumor board decision and specialist assessment

Exclusion Criteria

Patients who cannot lie for longer than 15 minutes.
Patients who are to receive radiotherapy of the lymphatic drainage are not included in this study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is to test the hypothesis, whether with standard PTV safety margins, ART provides dosimetric advantages over IGRT in more than 10% of patients with postoperative radiotherapy (H1).

Secondary Outcome Measures

Name	Time	Method
The secondary endpoint is to evaluate, whether cases with an EUD<95% can be identified with the accumulated dose distribution early during the treatment series based on the EUD values for the individual fractions.<br>Furthermore, the extent to which the planning safety margins around the CTV can be reduced to compensate for movements and deformations with online-adaptive radiotherapy (ART) compared to IGRT will be examined.